cilastatin has been researched along with Kidney Diseases in 19 studies
*Kidney Diseases: Pathological processes of the KIDNEY or its component tissues. [MeSH]
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 6 (31.58) | 18.7374 |
| 1990's | 7 (36.84) | 18.2507 |
| 2000's | 1 (5.26) | 29.6817 |
| 2010's | 3 (15.79) | 24.3611 |
| 2020's | 2 (10.53) | 2.80 |
| Authors | Studies |
|---|---|
| Becerir, T; Tokgün, O; Yuksel, S | 1 |
| Elyasi, S; Shayan, M | 1 |
| Humanes, B; Jado, JC; Lazaro, A; Tejedor, A | 1 |
| Nasri, H; Nematbakhsh, M | 1 |
| Ha, JR; Kim, BO; Kim, HG; Kim, JG; Kim, JM; Lee, DG; Lee, JM; Lee, SH; Oh, SW | 1 |
| Blanco-Codesido, M; Camano, S; Gomez-Gomez, MM; Humanes, B; Lara, JM; Lazaro, A; Lazaro, JA; Martín-Vasallo, P; Moreno-Gordaliza, E; Ortiz, A; Tejedor, A | 1 |
| Birnbaum, J; Kahan, FM; Kropp, H; Sundelof, JG | 1 |
| Claude, JR; Debray, M; Dutertre-Catella, H; Martin, C; Pham-Huy, C; Podevin, RA; Thevenin, M; Warnet, JM | 1 |
| Drechsel, J; Hammer, C; Markewitz, A; Pfeiffer, M; Reichart, B; Reichenspurner, H; Zahn, S | 1 |
| Boggi, U; Carmellini, M; Filipponi, F; Frosini, F; Mosca, F | 1 |
| Hosoya, J; Nakagawa, Y; Takahashi, S; Toyoguchi, T; Watanabe, H | 1 |
| Desaty, TM; Griffin, TJ; Heifetz, CL; Sesnie, JC; Shapiro, MA | 1 |
| Bland, JA; Graziani, AL; Lawson, LA; MacGregor, RR; Pietroski, NA; Rogers, JD | 1 |
| Abel, SR; Guba, EA | 1 |
| Kodama, H; Konishi, Y; Kumon, H; Nasu, Y; Ohmori, H | 1 |
| Drusano, GL | 1 |
| Bland, JA; Demetriades, JL; Gibson, TP | 1 |
| Alpert, G; Bloh, AM; Campos, JM; Connor, E; Dagan, R; Plotkin, SA; Powell, KR | 1 |
3 review(s) available for cilastatin and Kidney Diseases
| Article | Year |
|---|---|
Cilastatin as a protective agent against drug-induced nephrotoxicity: a literature review.
Topics: Animals; Apoptosis; Cilastatin; Humans; Kidney Diseases; Protease Inhibitors; Protective Agents; Reactive Oxygen Species | 2020 |
Thienamycin: development of imipenen-cilastatin.
Topics: Animals; Bacteria; beta-Lactamases; Chemical Phenomena; Chemistry; Cilastatin; Cyclopropanes; Dipeptidases; Drug Resistance, Microbial; Humans; Imipenem; Kidney Diseases; Thienamycins | 1983 |
An overview of the pharmacology of imipenem/cilastatin.
Topics: Cilastatin; Cyclopropanes; Dipeptidases; Humans; Imipenem; Kidney; Kidney Diseases; Kinetics; Thienamycins | 1986 |
2 trial(s) available for cilastatin and Kidney Diseases
| Article | Year |
|---|---|
Reduction of cyclosporine-induced nephrotoxicity by cilastatin following clinical heart transplantation.
Topics: 6-Ketoprostaglandin F1 alpha; Acetylglucosaminidase; Adolescent; Adult; Blood Urea Nitrogen; Cilastatin; Creatinine; Cyclosporine; Female; Heart Transplantation; Hemofiltration; Humans; Kidney Diseases; Male; Middle Aged; Single-Blind Method; Thromboxane B2 | 1994 |
Effect of cilastatin on cyclosporine-induced acute nephrotoxicity in kidney transplant recipients.
Topics: Acute Disease; Adult; Cadaver; Cilastatin; Creatinine; Cyclosporine; Female; Graft Survival; Humans; Kidney Diseases; Kidney Transplantation; Male; Middle Aged; Prospective Studies; Protease Inhibitors | 1997 |
14 other study(ies) available for cilastatin and Kidney Diseases
| Article | Year |
|---|---|
The therapeutic effect of Cilastatin on drug-induced nephrotoxicity: a new perspective.
Topics: Apoptosis; Cell Line; Cell Survival; Cilastatin; Cisplatin; Dose-Response Relationship, Drug; Gentamicins; HEK293 Cells; Hepatitis A Virus Cellular Receptor 1; Humans; Inhibitory Concentration 50; Kidney Diseases; Lipocalin-2; Oxidative Stress; Vancomycin | 2021 |
The authors reply.
Topics: Animals; Antineoplastic Agents; Apoptosis; Cilastatin; Cisplatin; Kidney; Kidney Diseases; Male; Protease Inhibitors | 2013 |
Cisplatin nephrotoxicity may be sex related.
Topics: Animals; Antineoplastic Agents; Apoptosis; Cilastatin; Cisplatin; Kidney; Kidney Diseases; Male; Protease Inhibitors | 2013 |
Comparison of in vivo nephrotoxicity in the rabbit by a pyrrolidinyl-thio Carbapenem CW-270031.
Topics: Animals; Anti-Bacterial Agents; Carbapenems; Cilastatin; Imipenem; Kidney; Kidney Diseases; Male; Meropenem; Pyrrolidines; Rabbits; Thienamycins | 2008 |
Cilastatin protects against cisplatin-induced nephrotoxicity without compromising its anticancer efficiency in rats.
Topics: Animals; Antineoplastic Agents; Apoptosis; Apoptosis Regulatory Proteins; Area Under Curve; Biomarkers; Blood Urea Nitrogen; Body Weight; Cell Line, Tumor; Cilastatin; Cisplatin; Creatinine; Cytoprotection; Dipeptidases; Disease Models, Animal; Dose-Response Relationship, Drug; Glomerular Filtration Rate; GPI-Linked Proteins; Kidney; Kidney Diseases; Male; Natriuresis; Oxidative Stress; Protease Inhibitors; Rats; Rats, Wistar; Swine | 2012 |
Rabbit renal proximal tubule suspensions as a model for nephrotoxicity evaluation of native or in situ metabolized beta-lactam antibiotics.
Topics: Adenosine Triphosphatases; Animals; Anti-Bacterial Agents; Cephaloridine; Cilastatin; Energy Metabolism; Female; Glutathione; Imipenem; In Vitro Techniques; Kidney Diseases; Kidney Tubules, Proximal; Rabbits | 1995 |
Nephrotoxicity of vancomycin and drug interaction study with cilastatin in rabbits.
Topics: Animals; Anti-Bacterial Agents; Blood Urea Nitrogen; Cilastatin; Creatinine; Dose-Response Relationship, Drug; Drug Interactions; Kidney; Kidney Diseases; Male; Organ Size; Protease Inhibitors; Rabbits; Vancomycin | 1997 |
Comparative therapeutic efficacy of clinafloxacin in a Pseudomonas aeruginosa mouse renal abscess model.
Topics: Abscess; Animals; Anti-Infective Agents; Area Under Curve; Ceftazidime; Cilastatin; Cilastatin, Imipenem Drug Combination; Ciprofloxacin; Colony Count, Microbial; Disease Models, Animal; Dose-Response Relationship, Drug; Drug Combinations; Drug Therapy, Combination; Female; Fluoroquinolones; Half-Life; Imipenem; Kidney; Kidney Diseases; Mice; Microbial Sensitivity Tests; Pseudomonas aeruginosa; Pseudomonas Infections; Quinolones; Treatment Outcome | 1998 |
Steady-state pharmacokinetics of intramuscular imipenem-cilastatin in elderly patients with various degrees of renal function.
Topics: Aged; Anti-Bacterial Agents; Cilastatin; Cilastatin, Imipenem Drug Combination; Drug Combinations; Half-Life; Humans; Imipenem; Injections, Intramuscular; Kidney Diseases | 1991 |
Evaluation of an imipenem/cilastatin target drug program.
Topics: Adult; Anti-Bacterial Agents; Bacteria, Anaerobic; Bacterial Infections; Central Nervous System Diseases; Cilastatin; Cilastatin, Imipenem Drug Combination; Cost Savings; Drug Combinations; Drug Costs; Drug Monitoring; Gram-Negative Bacteria; Gram-Positive Bacteria; Humans; Imipenem; Kidney Diseases; Pharmacy Service, Hospital | 1991 |
[Outline of imipenem/cilastatin sodium].
Topics: Abnormalities, Drug-Induced; Animals; Bacteria; Cilastatin; Cyclopropanes; Drug Combinations; Female; Imipenem; Kidney Diseases; Male; Mice; Pregnancy; Rats; Thienamycins | 1986 |
[Effects of cilastatin sodium, an inhibitor of dehydropeptidase-I, on human urinary peptide excretion. Patients with renal insufficiency].
Topics: Aged; Amino Acids; Cilastatin; Cyclopropanes; Dipeptidases; Drug Combinations; Humans; Imipenem; Kidney Diseases; Middle Aged; Peptides; Thienamycins | 1987 |
Imipenem/cilastatin: pharmacokinetic profile in renal insufficiency.
Topics: Cilastatin; Cyclopropanes; Drug Combinations; Humans; Imipenem; Kidney; Kidney Diseases; Kinetics; Metabolic Clearance Rate; Renal Dialysis; Thienamycins | 1985 |
Imipenem/cilastatin for the treatment of infections in hospitalized children.
Topics: Arthritis, Infectious; Bacterial Infections; Cellulitis; Child; Child, Preschool; Cilastatin; Cyclopropanes; Dipeptidases; Drug Combinations; Escherichia coli Infections; Female; Haemophilus Infections; Hospitalization; Humans; Imipenem; Infant; Kidney Diseases; Lymphadenitis; Male; Prospective Studies; Pseudomonas Infections; Staphylococcal Infections; Streptococcal Infections; Thienamycins; Wound Infection | 1985 |